KRAS and non-small cell lung carcinoma: In a prospective study that included 69 patients with advanced NSCLC, dynamic changes in ctDNA and plasma mutant KRAS (pmKRAS) in NSCLC patients during treatment were found, and the prognostic value of evaluating the content of ctDNA was also shown.